rocketman2 I'm not sure what you mean by a "generic publicacation regarding breast cancer" but the note I, and I'm sure others, got from Zenith referenced a publication in Nature Publishing Group's Journal of Cancer Gene Therapy. The article is very specific to a Zen 3694 combination for ER+ve breast cancer and quite detailed. 

RVXOT I saw that pp also. It is very disappointing that despite all the positive going on at Zenith and the sale of Constellation (a mid stage epigenetic company) for $1.7B USD that Don is selling Zenith shares that value the company at roughly $200M USD.